Literature DB >> 17549303

Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans.

Matthias Watzka1, Almut Nebel, Nour Eddine El Mokhtari, Boris Ivandic, Jens Müller, Stefan Schreiber, Johannes Oldenburg.   

Abstract

Recently, the C-allele of polymorphism rs2359612 (VKORC1: c.283+837C>T) in the VKORC1 gene has been reported to represent a major risk factor for coronary heart disease (CHD), stroke, and aortic dissection in Chinese patients. VKOR activity itself is the rate-limiting step in gamma-carboxylation of vitamin K-dependent coagulation factors (factors II, VII, IX, X, protein C, S, and Z) and proteins of calcium metabolism (matrix Gla protein and osteocalcin). Gamma-carboxylation is essential for the biological activity of these proteins that have been previously hypothesised to play a role in the pathogenesis of atherosclerosis. It was the objective of this study to analyse the VKORC1 genotype frequency in patients with CHD and controls from Northern Germany and to investigate the association of VKORC1 and CHD risk in patients with an European background. CHD patients (n = 901) and healthy controls (n = 521) were part of the PopGen biobank. Case and control samples were matched for ethnic and geographic origin, age and gender. After typing German CHD patients and control individuals, no evidence for a statistically significant association was detected between VKORC1 genotype and CHD phenotype. Also stratification for gender and myocardial infarction yielded no significant results. In conclusion, the discrepant association findings in Chinese and German populations may be explained by ethnic differences in genetic and perhaps environmental predisposition, modifying the polygenic CHD phenotype by interacting with VKORC1 variants and thus conferring disease susceptibility in some populations, but not in others.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549303

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up.

Authors:  Carlo Giansante; Nicola Fiotti; Nicola Altamura; Paola Pitacco; Lara Consoloni; Sabino Scardi; Carmine Mazzone; Gabriele Grassi; Claudio Pandullo; Andrea Di Lenarda
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

2.  To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study.

Authors:  Xiaotong Xia; Nianxu Huang; Boxia Li; Yan Li; Lang Zou; Dongdong Yuan; Banghua Huang; Yufei Bei; Yuxin Liu; Jinglan Fu; Tingting Wu; Wenjun Chen; Shaojun Jiang; Meina Lv; Jinhua Zhang
Journal:  Eur J Clin Pharmacol       Date:  2021-08-28       Impact factor: 2.953

3.  Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.

Authors:  Danxin Wang; Huizi Chen; Kathryn M Momary; Larisa H Cavallari; Julie A Johnson; Wolfgang Sadée
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

4.  G-1639A but Not C1173T VKORC1 Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population.

Authors:  Yevhen I Dubovyk; Viktoriia Yu Harbuzova; Alexander V Ataman
Journal:  Biomed Res Int       Date:  2016-09-15       Impact factor: 3.411

5.  VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation.

Authors:  Milka Marinova; Dieter Lütjohann; Olof Breuer; Heike Kölsch; Philipp Westhofen; Matthias Watzka; Martin Mengel; Birgit Stoffel-Wagner; Gunther Hartmann; Christoph Coch; Johannes Oldenburg
Journal:  Eur J Clin Pharmacol       Date:  2012-08-05       Impact factor: 2.953

6.  Association of functional VKORC1 promoter polymorphism with occurrence and clinical aspects of ischemic stroke in a Greek population.

Authors:  Georgia Ragia; Stella Marousi; John Ellul; Vangelis G Manolopoulos; Anna Tavridou
Journal:  Dis Markers       Date:  2013-10-31       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.